Tobramycin

CHEMBL1747 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

467.5 g/mol

LogP

-6.2

Phase

4

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

분자량

467.5000 g/mol

LogP

-6.20

TPSA

268.00 Å²

리핀스키 5의 법칙

불통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Chronic Kidney Disease Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O

InChI

InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

Molecular Formula

C18H37N5O9

HBD / HBA

10 / 14

회전 가능 결합

6

무거운 원자

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

Yes, Tobramycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1747. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36294. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Tobramycin PillFYI에서

구조

핵심 데이터

분자식: C18H37N5O9
동의어: 9

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.